Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Semjonow

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
European Urology|May 28, 2013
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trialChristian Arsov, Nikolaus Becker, Boris A Hadaschik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95Thomas Wiegel, Dirk Bottke, Ursula Steiner, et al.
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
Prostate Cancer|August 28, 2018
The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological OutcomesDianne van Strijp, Christiane de Witz, Pieter C Vos, et al.
Scientific Reports|December 7, 2021
Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trialDorothee Tiedje, Matthias Borowski, Alexandra Simbrich, et al.
European Urology|April 1, 2014
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
European Urology|January 23, 2019
Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69Yr: The PSAInForm TrialAxel Semjonow, Hans-Werner Hense, Kathrin Schlößler, et al.
European Urology Open Science|July 11, 2022
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 InitiativeSebastiaan Remmers, Jozien Helleman, Daan Nieboer, et al.
European Urology|November 7, 2018
A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian SettingsPeter K-F Chiu, Chi-Fai Ng, Axel Semjonow, et al.
Critical Reviews in Oncology/Hematology|August 11, 2012
Active surveillance for low-risk prostate cancerChris H Bangma, Meelan Bul, Theo H van der Kwast, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
European Urology|May 28, 2013
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trialChristian Arsov, Nikolaus Becker, Boris A Hadaschik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95Thomas Wiegel, Dirk Bottke, Ursula Steiner, et al.
International Journal of Radiation Oncology, Biology, Physics|December 3, 2014
Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
Prostate Cancer|August 28, 2018
The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological OutcomesDianne van Strijp, Christiane de Witz, Pieter C Vos, et al.
Scientific Reports|December 7, 2021
Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trialDorothee Tiedje, Matthias Borowski, Alexandra Simbrich, et al.
European Urology|April 1, 2014
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trialThomas Wiegel, Detlef Bartkowiak, Dirk Bottke, et al.
European Urology|January 23, 2019
Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69Yr: The PSAInForm TrialAxel Semjonow, Hans-Werner Hense, Kathrin Schlößler, et al.
European Urology Open Science|July 11, 2022
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 InitiativeSebastiaan Remmers, Jozien Helleman, Daan Nieboer, et al.
European Urology|November 7, 2018
A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian SettingsPeter K-F Chiu, Chi-Fai Ng, Axel Semjonow, et al.
Critical Reviews in Oncology/Hematology|August 11, 2012
Active surveillance for low-risk prostate cancerChris H Bangma, Meelan Bul, Theo H van der Kwast, et al.
Pageof 11